Palavra-chave: CHRONIC MYELOID LEUKEMIA

EBMT RISK SCORES BCR-ABL1 CYTOGENETIC P190, P120, P230 JAK2 V617F COVID19 AUTOGRAFTING T315L ENESTND OCULAR IMATINIB EBMT PHASE 2 SECOND-GENERATION IMATINIB-RESISTANT EUTOS SCORE CLINICAL TRIAL IMATINIB RESISTANCE LASOR DENATURING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY AUTOGRAFTING OF PERIPHERAL-BLOOD B3A2 EXPRESSION PF P190 IMATINIB MESILATE PH CHROMOSSOME MUTATION MITOXANTRONE T315I MOLECULAR GENE EXPRESSION PROFILE TK INHIBITORS BRAZILIAN MEDICAL ASSOCIATION EXON 6 NON-MYELOABLATIVE HMGCLL1 CHRONIC PHASE TYROSINE KINASE INHIBITORS IRS-1 FEDERAL UNIVERSITY OF MINAS GERAIS DASATINIB-TREATED DASATINIB IMATINIB-RESISTANT OR-INTOLERANT RT-PCR NEW DRUGS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION BONE MARROW TRANSPLANTATION INTERFERON-ALPHA DHPLC K562 CELLS EXPANDING NILOTINIB ACESS IN CLINICAL TRIALS NILOTINIB START CYTARABINE BCR-ABL FISH D-HPLC STATE UNIVERSITY OF CAMPINAS PROGRESSION-FREE SURVIVAL STEM CELL TRANSPLANTATION F359V TREATMENT-FREE REMISSION SUBOPTIMAL RESPONSES DISCONTINUATION GLEEVEC CML PERIPHERAL BLOOD STEM CELL TRANSPLANTS